EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • March 1st, 2017 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Agreement”) is made and entered into effective as of January 6, 2011 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EX-10 3 f8kex10.htm EXCLUSIVE CHANNEL PARTNER AGREEMENT FOR THE LICENSING OF BRAINTECH'S VISION GUIDED ROBOTICS TECHNOLOGIES AND SOFTWARE PRODUCTS PARTIES:Exclusive Channel Partner Agreement • May 5th, 2020 • Michigan
EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Agreement”) is made and entered into effective as of January 6, 2011 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party”, and collectively as the “Parties.”
THIRD AMENDMENT TO EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • June 30th, 2016 • Intrexon Corp • Services-commercial physical & biological research
This THIRD AMENDMENT TO THE EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Third Amendment”) is effective as of June 29, 2016 (the “Third Amendment Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”) and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • April 2nd, 2015 • Intrexon Corp • Services-commercial physical & biological research
This SECOND AMENDMENT TO THE EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Amendment”) is effective as of March 27, 2015 (the “Amendment Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”) and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • May 3rd, 2012 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec
THIS FIRST AMENDMENT is entered into as of this 13th day of September, 2011 and serves to amend the Exclusive Channel Partner Agreement entered into by and between Intrexon Corporation (“Intrexon”) and ZIOPHARM Oncology, Inc. (“ZIOPHARM”), on January 6, 2011 (the “Agreement”).
ContractExclusive Channel Partner Agreement • May 5th, 2020 • New York
EX-10.1 2 v207772_ex10-1.htm Exhibit 10.1 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Exclusive Channel Partner Agreement This Exclusive Channel Partner Agreement (the “Agreement”) is made and entered into effective as of January 6, 2011 (the “Effective Date”) by and between Intrexon Corporation, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ZIOPHARM Oncology, Inc., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party”, and collectively as the “Parties.” Recitals Whereas, Intrexon has expertise in and owns or controls proprietary technolog
THIRD AMENDMENT TO EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • June 30th, 2016 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec
This THIRD AMENDMENT TO THE EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Third Amendment”) is effective as of June 29, 2016 (the “Third Amendment Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”) and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party” and collectively as the “Parties.”
